Helix BioMedix Completes $2 Million Private Placement to Advance Xeroderma Pigmentosum Development Program
Financing strengthens balance sheet and accelerates advancement of proprietary DNA repair technology targeting UV-induced DNA damage.
Bothell, WA, August 29, 2026 --(PR.com)-- Helix BioMedix, Inc. (OTCIQ: HXBM), a preclinical stage biotechnology company currently focused on developing innovative DNA repair therapeutics for severe dermatological diseases, today announced the completion of a private placement financing on August 25, 2026, generating gross cash proceeds of $2 million.
Under the terms of the financing, the Company issued 100,000 shares of common stock to an accredited investor, who is a current stockholder of the Company holding over 50% of the Company’s outstanding securities, at a purchase price of $20.00 per share. Under the investment, the investor holds two special rights. First, a one-time discount right to purchase securities in the Company's next qualified financing at 80% of the lowest per-share price paid by any other investor in that round, exercisable at the round's initial closing. Second, weighted-average anti-dilution protection: if the Company's first down-round financing (below the $20.00 per-share reference price) occurs within 36 months of closing, the investor will receive additional "top-up" shares at no cost to offset the lower price. Both rights are one-time only and expire on the earlier of 36 months after the closing date or, with respect to the discount right, the Company's next qualified financing, and, with respect to the anti-dilution projection, the Company’s first down-round.
The proceeds will be used primarily to advance Helix BioMedix's lead development program for Xeroderma Pigmentosum (XP), an ultra-rare genetic disease characterized by defective DNA repair mechanisms that leave patients highly vulnerable to ultraviolet (UV) radiation-induced DNA damage and significantly increased skin cancer risk.
The financing further strengthens the Company's balance sheet and provides additional resources to support ongoing preclinical development activities, regulatory planning, and key milestones designed to position the XP program for future clinical advancement.
"This financing represents an important milestone for Helix BioMedix as we continue advancing our proprietary DNA repair technology toward the clinic," said Robin L. Carmichael, Chief Executive Officer of Helix BioMedix. "We believe the support from this investor reflects growing confidence in our scientific approach, our development strategy, and the potential for our technology to address a profound unmet medical need in patients living with Xeroderma Pigmentosum. With this capital, we are better positioned to execute on critical development objectives and to work to create long-term value for both patients and shareholders."
The securities were offered and sold in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506 of Regulation D promulgated thereunder, in reliance on representations that the investor is an "accredited investor" as defined in Rule 501(a) of Regulation D.
Addressing a Significant Unmet Medical Need
Helix BioMedix's lead program is focused on developing a first-in-class therapeutic approach designed to repair UV-induced DNA damage in the skin of patients with XP. The Company’s polypeptide DNA Damage Response (DDR) enzyme is based on repair pathways necessary to prevent cancerous mutations and maintain skin homeostasis. Individuals with XP pigmentosum are 10,000 times more likely to develop non-melanoma skin cancer and up to 2,000 times more likely to develop melanoma skin cancer compared to individuals without this condition.1 Current management of XP relies heavily on strict avoidance of UV exposure and intensive surveillance for skin cancers, underscoring the need for innovative therapies that address the underlying biological cause of the disease.
The Company believes its proprietary DNA damage response technology has the potential to provide a novel treatment approach that could meaningfully improve outcomes and quality of life for individuals affected by this devastating ultra-rare disease.
About Helix BioMedix, Inc.
Helix BioMedix is a biotechnology company dedicated to the discovery and development of innovative therapeutics focused on dermatology, skin health, and DNA repair technologies. The Company's lead development program targets Xeroderma Pigmentosum (XP), an ultra- rare genetic disorder caused by defects in DNA repair pathways that result in extreme sensitivity to ultraviolet radiation and substantially elevated skin cancer risk.
Leveraging its expertise in skin biology and DNA damage repair, Helix BioMedix is advancing novel therapeutic approaches intended to address the underlying causes of disease and improve the lives of patients with significant unmet medical needs. The Company also maintains a legacy peptide technology platform supporting select applications in personal care and related markets.
Forward Looking Statements
This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to potential growth and long-term value creation, the company’s intended use of proceeds from the private placement, continued product development, the advancement and feasibility of its rare disease program, the potential benefits of such program, ongoing and planned preclinical development activities, potential clinical and regulatory progress, and the Company’s expectations regarding future financing, commercialization, licensing, and development opportunities. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully use the proceeds of the financing as planned, raise additional capital on acceptable terms, if at all, develop safe and effective therapeutic candidates, obtain favorable regulatory feedback or authorization to proceed with additional studies, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, manage patent and commercialization risks, and respond to general economic conditions, including tariff-related uncertainty. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
1 https://medlineplus.gov/genetics/condition/xeroderma-pigmentosum/
For more information, please visit:
www.Helix BioMedix.com
Investor Contact:
Robin L. Carmichael
CEO, Helix BioMedix, Inc.
ir@helixbiomedix.com
Under the terms of the financing, the Company issued 100,000 shares of common stock to an accredited investor, who is a current stockholder of the Company holding over 50% of the Company’s outstanding securities, at a purchase price of $20.00 per share. Under the investment, the investor holds two special rights. First, a one-time discount right to purchase securities in the Company's next qualified financing at 80% of the lowest per-share price paid by any other investor in that round, exercisable at the round's initial closing. Second, weighted-average anti-dilution protection: if the Company's first down-round financing (below the $20.00 per-share reference price) occurs within 36 months of closing, the investor will receive additional "top-up" shares at no cost to offset the lower price. Both rights are one-time only and expire on the earlier of 36 months after the closing date or, with respect to the discount right, the Company's next qualified financing, and, with respect to the anti-dilution projection, the Company’s first down-round.
The proceeds will be used primarily to advance Helix BioMedix's lead development program for Xeroderma Pigmentosum (XP), an ultra-rare genetic disease characterized by defective DNA repair mechanisms that leave patients highly vulnerable to ultraviolet (UV) radiation-induced DNA damage and significantly increased skin cancer risk.
The financing further strengthens the Company's balance sheet and provides additional resources to support ongoing preclinical development activities, regulatory planning, and key milestones designed to position the XP program for future clinical advancement.
"This financing represents an important milestone for Helix BioMedix as we continue advancing our proprietary DNA repair technology toward the clinic," said Robin L. Carmichael, Chief Executive Officer of Helix BioMedix. "We believe the support from this investor reflects growing confidence in our scientific approach, our development strategy, and the potential for our technology to address a profound unmet medical need in patients living with Xeroderma Pigmentosum. With this capital, we are better positioned to execute on critical development objectives and to work to create long-term value for both patients and shareholders."
The securities were offered and sold in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506 of Regulation D promulgated thereunder, in reliance on representations that the investor is an "accredited investor" as defined in Rule 501(a) of Regulation D.
Addressing a Significant Unmet Medical Need
Helix BioMedix's lead program is focused on developing a first-in-class therapeutic approach designed to repair UV-induced DNA damage in the skin of patients with XP. The Company’s polypeptide DNA Damage Response (DDR) enzyme is based on repair pathways necessary to prevent cancerous mutations and maintain skin homeostasis. Individuals with XP pigmentosum are 10,000 times more likely to develop non-melanoma skin cancer and up to 2,000 times more likely to develop melanoma skin cancer compared to individuals without this condition.1 Current management of XP relies heavily on strict avoidance of UV exposure and intensive surveillance for skin cancers, underscoring the need for innovative therapies that address the underlying biological cause of the disease.
The Company believes its proprietary DNA damage response technology has the potential to provide a novel treatment approach that could meaningfully improve outcomes and quality of life for individuals affected by this devastating ultra-rare disease.
About Helix BioMedix, Inc.
Helix BioMedix is a biotechnology company dedicated to the discovery and development of innovative therapeutics focused on dermatology, skin health, and DNA repair technologies. The Company's lead development program targets Xeroderma Pigmentosum (XP), an ultra- rare genetic disorder caused by defects in DNA repair pathways that result in extreme sensitivity to ultraviolet radiation and substantially elevated skin cancer risk.
Leveraging its expertise in skin biology and DNA damage repair, Helix BioMedix is advancing novel therapeutic approaches intended to address the underlying causes of disease and improve the lives of patients with significant unmet medical needs. The Company also maintains a legacy peptide technology platform supporting select applications in personal care and related markets.
Forward Looking Statements
This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to potential growth and long-term value creation, the company’s intended use of proceeds from the private placement, continued product development, the advancement and feasibility of its rare disease program, the potential benefits of such program, ongoing and planned preclinical development activities, potential clinical and regulatory progress, and the Company’s expectations regarding future financing, commercialization, licensing, and development opportunities. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully use the proceeds of the financing as planned, raise additional capital on acceptable terms, if at all, develop safe and effective therapeutic candidates, obtain favorable regulatory feedback or authorization to proceed with additional studies, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, manage patent and commercialization risks, and respond to general economic conditions, including tariff-related uncertainty. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
1 https://medlineplus.gov/genetics/condition/xeroderma-pigmentosum/
For more information, please visit:
www.Helix BioMedix.com
Investor Contact:
Robin L. Carmichael
CEO, Helix BioMedix, Inc.
ir@helixbiomedix.com
Contact
Helix BioMedix, Inc
Kelly Forsythe
425-686-1006
www.helixbiomedix.com
Kelly Forsythe
425-686-1006
www.helixbiomedix.com
Contact
Categories